Jaap Verweij

70.5k total citations · 12 hit papers
621 papers, 55.4k citations indexed

About

Jaap Verweij is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jaap Verweij has authored 621 papers receiving a total of 55.4k indexed citations (citations by other indexed papers that have themselves been cited), including 396 papers in Oncology, 210 papers in Molecular Biology and 194 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jaap Verweij's work include Cancer therapeutics and mechanisms (158 papers), Cancer Treatment and Pharmacology (145 papers) and Sarcoma Diagnosis and Treatment (106 papers). Jaap Verweij is often cited by papers focused on Cancer therapeutics and mechanisms (158 papers), Cancer Treatment and Pharmacology (145 papers) and Sarcoma Diagnosis and Treatment (106 papers). Jaap Verweij collaborates with scholars based in Netherlands, United States and Belgium. Jaap Verweij's co-authors include M. van Glabbeke, Alex Sparreboom, Allan T. van Oosterom, J. Wanders, Elizabeth A. Eisenhauer, Patrick Therasse, Larry Rubinstein, Richard Kaplan, Susan G. Arbuck and Michaele C. Christian and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jaap Verweij

617 papers receiving 53.9k citations

Hit Papers

New Guidelines to Evaluate the Response to Treatment in S... 2000 2026 2008 2017 2000 2006 2001 2004 2001 4.0k 8.0k 12.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. New Guidelines to Evaluate the Response to Treatment in Solid Tumors
    2000 13.6k citations J. Wanders, Jaap Verweij et al. profile →
  2. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    2006 1.9k citations George D. Demetri, Christopher R. Garrett et al. profile →
  3. Cremophor EL
    2001 1.4k citations Jaap Verweij, Kees Nooter et al. profile →
  4. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    2004 1.3k citations Jaap Verweij, Paolo G. Casali et al. profile →
  5. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
    2001 975 citations Ian Judson, Jaap Verweij et al. profile →
  6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
    2014 814 citations Ian Judson, Jaap Verweij et al. profile →
  7. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    2006 654 citations Axel Le Cesne, Jean‐Yves Blay et al. profile →
  8. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
    2009 624 citations M. van Glabbeke, Axel Le Cesne et al. profile →
  9. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    2011 550 citations Jaap Verweij et al. Journal of Clinical Oncology profile →
  10. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
  11. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
    2010 486 citations Jaap Verweij, Jean‐Yves Blay et al. profile →
  12. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
    2012 383 citations Axel Le Cesne, Michael Leahy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaap Verweij Netherlands 100 28.2k 22.3k 13.7k 8.8k 6.7k 621 55.4k
David Cunningham United Kingdom 120 42.1k 1.5× 30.7k 1.4× 12.7k 0.9× 24.5k 2.8× 6.4k 1.0× 1.2k 77.9k
Jean‐Yves Blay France 109 19.4k 0.7× 26.9k 1.2× 5.5k 0.4× 7.3k 0.8× 9.3k 1.4× 1.2k 45.8k
Cornelis J.�H. van de Velde Netherlands 96 27.5k 1.0× 14.4k 0.6× 5.2k 0.4× 21.3k 2.4× 3.3k 0.5× 688 47.9k
Heikki Joensuu Finland 97 12.8k 0.5× 12.6k 0.6× 8.4k 0.6× 7.1k 0.8× 9.3k 1.4× 583 35.5k
Yung‐Jue Bang South Korea 87 20.9k 0.7× 17.1k 0.8× 10.8k 0.8× 7.6k 0.9× 4.5k 0.7× 610 37.1k
Samuel Singer United States 90 8.1k 0.3× 16.7k 0.7× 7.3k 0.5× 4.9k 0.6× 7.0k 1.0× 331 28.9k
George D. Demetri United States 93 11.1k 0.4× 23.7k 1.1× 6.6k 0.5× 8.9k 1.0× 17.0k 2.5× 346 38.0k
Ian Judson United Kingdom 79 10.8k 0.4× 16.5k 0.7× 6.0k 0.4× 5.0k 0.6× 6.4k 1.0× 403 28.0k
Murray F. Brennan United States 143 38.6k 1.4× 43.3k 1.9× 5.6k 0.4× 31.6k 3.6× 10.5k 1.6× 954 81.0k
John L. Cameron United States 118 40.4k 1.4× 21.5k 1.0× 7.4k 0.5× 35.3k 4.0× 2.8k 0.4× 531 62.4k

Countries citing papers authored by Jaap Verweij

Since Specialization
Citations

This map shows the geographic impact of Jaap Verweij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaap Verweij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaap Verweij more than expected).

Fields of papers citing papers by Jaap Verweij

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaap Verweij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaap Verweij. The network helps show where Jaap Verweij may publish in the future.

Co-authorship network of co-authors of Jaap Verweij

This figure shows the co-authorship network connecting the top 25 collaborators of Jaap Verweij. A scholar is included among the top collaborators of Jaap Verweij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaap Verweij. Jaap Verweij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations
2.
Graan, Anne‐Joy M. de, Laure Elens, Jason A. Sprowl, et al.. (2013). CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research. 19(12). 3316–3324. 91 indexed citations
3.
Eechoute, Karel, Martin N. Fransson, Floris A. de Jong, et al.. (2012). A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research. 18(20). 5780–5787. 87 indexed citations
4.
Banerji, Udai, Leni van Doorn, Dionysis Papadatos-Pastos, et al.. (2012). A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research. 18(9). 2687–2694. 64 indexed citations
5.
Demetri, George D., Patrick Schöffski, Manisha H. Shah, et al.. (2012). Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research. 18(11). 3170–3179. 102 indexed citations
6.
Graan, Anne‐Joy M. de, Walter J. Loos, Lena E. Friberg, et al.. (2012). Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. Clinical Cancer Research. 18(16). 4425–4432. 29 indexed citations
7.
Eskens, Ferry A.L.M., Maja J.A. de Jonge, Pankaj Bhargava, et al.. (2011). Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(22). 7156–7163. 89 indexed citations
8.
Bol, Jessica M. van der, Ron H.J. Mathijssen, Geert-Jan Creemers, et al.. (2010). A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clinical Cancer Research. 16(2). 736–742. 50 indexed citations
9.
DePrimo, Samuel E., Xin Huang, Martin E. Blackstein, et al.. (2009). Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure. Clinical Cancer Research. 15(18). 5869–5877. 38 indexed citations
10.
Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →
11.
Baird, Richard D., Jos Kitzen, Paul A. Clarke, et al.. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(6). 1430–1437. 33 indexed citations
12.
Mom, Constantijne H., Jaap Verweij, Corina N.A.M. Oldenhuis, et al.. (2009). Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clinical Cancer Research. 15(17). 5584–5590. 85 indexed citations
13.
Ray‐Coquard, Isabelle, Axel Le Cesne, Jeremy Whelan, et al.. (2008). A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. The Oncologist. 13(4). 467–473. 48 indexed citations
14.
15.
Kroetz, Deanna L., H. L. McLeod, Lena E. Friberg, et al.. (2006). Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein. Clinical Pharmacology & Therapeutics. 81(1). 42–49. 131 indexed citations
16.
Burger, Herman, Hans van Tol, Mariël Brok, et al.. (2005). Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biology & Therapy. 4(7). 747–752. 159 indexed citations
17.
Bruijn, Peter de, Edwin W Willems, Walter J. Loos, Jaap Verweij, & Alex Sparreboom. (2004). Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Analytical Biochemistry. 328(1). 84–86. 15 indexed citations
18.
Mathijssen, Ron H.J., Sharon Marsh, Mats O. Karlsson, et al.. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics.. PubMed. 9(9). 3246–53. 209 indexed citations
19.
McLeod, HL, J. Wanders, A Setanoians, et al.. (1996). Multicentre phase II pharmacological evaluation of rhizoxin. British Journal of Cancer. 74(12). 1944–1948. 32 indexed citations
20.
Verweij, Jaap, Hans Herweijer, R. Oosterom, et al.. (1991). A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. British Journal of Cancer. 64(2). 361–364. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Cunningham Breakdown of academic impact, for papers by Jean‐Yves Blay Breakdown of academic impact, for papers by Cornelis J.�H. van de Velde Breakdown of academic impact, for papers by Heikki Joensuu Breakdown of academic impact, for papers by Yung‐Jue Bang Breakdown of academic impact, for papers by Samuel Singer Breakdown of academic impact, for papers by George D. Demetri Breakdown of academic impact, for papers by Ian Judson Breakdown of academic impact, for papers by Murray F. Brennan Breakdown of academic impact, for papers by John L. Cameron
Rankless by CCL
2026